Last reviewed · How we verify
Merck Glucophage® high dose — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Merck Glucophage® high dose (Merck Glucophage® high dose) — Boehringer Ingelheim.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Merck Glucophage® high dose TARGET | Merck Glucophage® high dose | Boehringer Ingelheim | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Merck Glucophage® high dose CI watch — RSS
- Merck Glucophage® high dose CI watch — Atom
- Merck Glucophage® high dose CI watch — JSON
- Merck Glucophage® high dose alone — RSS
Cite this brief
Drug Landscape (2026). Merck Glucophage® high dose — Competitive Intelligence Brief. https://druglandscape.com/ci/merck-glucophage-high-dose. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab